Introducing VOL.U.LIFT™
First-To-Market Innovation to address visible side effects of GLP-1 induced rapid weight loss on facial skin
Designed as the first-of-its-kind, all-in-one treatment, VOL.U.LIFT™ was expertly formulated based on in-depth research into how skin responds to rapid weight loss from GLP-1 use and similar therapies—known to accelerate visible signs of skin aging. This advanced formula is designed for both corrective and preventive use, combating facial changes using a multi-faceted approach, directly addressing the evolving needs of consumers. In partnership with leading dermatologist and integrative research doctor Raja Sivamani, clinical trials are already producing visible results in two weeks with participants.
VOL.U.LIFT™ is powered by IMAGE Skincare, the leading professional skincare brand in the spa and salon category as tracked by Kline & Co., and features the brand's proprietary XOSM™ Technology—a next-generation, patent-pending innovation, along with L-Ornithine amino acid which has been shown in external clinical studies to increase fatty tissue volume, reduce the appearance of structural aging and plump the skin.
"As a plastic surgeon, I am seeing firsthand the rapid rise in GLP-1 usage among patients and the subsequent long-term side effects that directly impact overall skin health. GLP-1-induced skin aging is a new phenomenon that is affecting patients in different ways. However, to date, there are no targeted solutions that address the distinct range of skin concerns that accompany these treatments. This is why I developed VOL.U.LIFT.™" – Dr.
"We are seeing patients on GLP-1 agonists lose up to 30% of muscle and connective tissue as a result of rapid weight loss- this impacts both the body and facial skin. The key is to supplement a protein-based diet with topical skincare that stimulates cell activity using clinically proven ingredients to jumpstart cell function, specifically addressing mechanisms that generate collagen, strengthen the skin structure and increase hydration." - Dr.
VOL.U.LIFT™ (
###
For more information on VOL.U.LIFT™ and the 12-week in-vivo clinical study performed on GLP-1 users, please reach out to the contact listed below.
Media Contact:
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/introducing-volulift-302421221.html
SOURCE IMAGE Skincare
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloomsbury Money Integrates ClearBank to Deepen Global Payment Capabilities
- ALSTOM S.A: Update on the AMF investigation opened in 2021/22
- WENDEL: David Darmon, Group Deputy CEO and member of Wendel’s Executive Board, will leave his position on November 30, 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share